Skip to content. | Skip to navigation

Navigation

DFM Chronicle  Check us out in the media

Postgraduate Residency Program Brochure

DFM House  MedPortal

 
You are here: Department of Family Medicine > Faculty > Faculty Listings > Dr. Dee Mangin

Dr. Dee Mangin

Dr. Dee Mangin
David Braley Health Sciences Centre
100 Main Street West
5th Floor

Hamilton , ON L8P 1H6
Office Phone: (905) 525-9140 x21685

Biography:

Dr. Dee Mangin, MBChB (Otago) DPH (Otago) FRNZCGP (NZ)

Academic Rank


Professor, Department of Family Medicine, McMaster University
Professor, University of Otago, Christchurch
David Braley & Nancy Gordon Chair in Family Medicine

Academic Leadership


Associate Chair, Research, Department of Family Medicine, McMaster University

Biography:

Before moving from New Zealand to Canada, Dee Mangin was the Director of the Primary Care Unit at the University of Otago, Christchurch, and Clinical Leader for Research Audit and Evaluation at the Pegasus Health Primary Healthcare Organisation.  She was a Ministerially appointed member of the New Zealand Pharmaceutical and Therapeutic Products Advisory Committee, PHARMAC.  She is a Fellow of the Royal New Zealand College of General Practitioners, and in 2011 she received their Distinguished Service Medal.  Dr. Mangin sits on the Section of Researchers' Council with the College of Family Physicians of Canada (CFPC) and is a member of the Integrated Patient Safety Action Plan Medication Safety Leads Group, Patients for Patient Safety Canada.  She was awarded both a Distinguished Paper and Best Paper award at the North American Primary Care Research Group's (NAPCRG) 2015 conference.  She is the Director of MUSIC, the McMaster University Sentinel and Information Collaboration practice-based research network, and the Medical Director and cofounder of RxISK.org a website for consumer information and reporting of drug adverse reactions.

Her broad interests are: rational prescribing; innovative models of primary care delivery; effective incorporation of evidence into patient centred practice; and the influences of science, policy and commerce on the nature of care.  She has wide clinical research experience in primary care, including observational and interventional quantitative research methods and community RCTs of innovative models of care.  Dr. Mangin has experience leading RCTs of clinical interventions in areas such as antidepressant use, community acquired pneumonia, antibiotics in urinary tract infections, deprescribing trials on the reduction of single medicines and deprescribing of multiple medicines among  older adults.

Dangerous Caring: How good medicine can be bad for your health (and how to avoid it)

University of Otago, Professorial Lecture

Special Interests:

  • Rational prescribing
  • Multimorbidity, polypharmacy and medication discontinuation
  • Patient centred care: effective integration of patient preferences and research evidence into treatment decisions
  • Innovative models of primary care
  • Medication safety

Selected Publications:

  • Dolovich L, Oliver D, Lamarche L, Agarwal G, Carr T, Chan D, Cleghorn L, Griffith L, Javadi D, Kastner M, Longaphy J, Mangin D, Papaioannou A, Ploeg J, Raina P, Richardson J, Risdon C, Santaguida P, Straus S, Thabane L, Valaitis R, Price D. (2016).  A protocol for a pragmatic randomized controlled trial using the Health Teams Advancing Patient Experience: Strengthening Quality (Health TAPESTRY) platform approach to promote person-focused primary healthcare for older adults. Implementation Science.11:49. doi: 10.1186/s13012-016-0407-5. http://www.implementationscience.com/content/11/1/49
  • Ailabouni N, Nishtala PS, Mangin D, Tordoff JM. (2016) Challenges and enablers of deprescribing: A General Practitioner Perspective. PLoS ONE 11(4): e0151066. doi:10.1371/journal.pone.0151066. http://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0151066
  • Ailabouni N, Nishtala PS, Mangin D, Tordoff JM.(2016). General practitioners' insight into deprescribing for the multimorbid older individual: a qualitative study. International Journal of Clinical Practice. 2016 Mar;70(3):261-76. doi: 10.1111/ijcp.12780.
  • Mangin D, Stephen G, Bismah V, Risdon C. (2016). Making patient preferences visible in healthcare: a systematic review of tools to assess patient treatment priorities and preferences in the context of multimorbidity. BMJ Open. 2016; 6:e010903. doi: :10.1136/bmjopen-2015-010903. http://bmjopen.bmj.com/content/6/6/e010903.long
  • Hudson B, Williman JA, Stamp LK, Alchin JS, Hooper GJ, Mangin D, Thompson BF, Toop L. (2015). Nortriptyline in knee osteoarthritis (NortIKA Study): Study protocol for a randomised controlled trial. Trials. 16(448). http://trialsjournal.biomedcentral.com/articles/10.1186/s13063-015-0961-1
  • Toop L, Mangin D. (2015). The art and science of marketing medications. NZMJ. 128(1421): 11-12.
  • Mangin D. (2015). Pay for performance (P4), targets and polypharmacy. Irish Ageing Studies Review. 6(1): 114.
  • Mangin D. (2015). The Antidepressant Cessation Trial study: Maintenance vs gradual withdrawal of fluoxetine in stable depression. Irish Ageing Studies Review. 6(1): 114.
  • Mangin D. (2015). How to involve patients in de-prescribing. Irish Ageing Studies Review. 6(1): 114-115.
  • Mangin D. (2015). Commercial influence on healthcare and its influence on polypharmacy. Irish Ageing Studies Review. 6(1): 114.
  • Mangin D, Heath I. (2015). Multimorbidity and Quaternary Prevention (P4). Rev Bras Med Fam Comunidade. 10(35): 1-5.
  • Birtwhistle R, Barber D, Drummond N, Godwin M, Greiver M, Singer A, Lussier MT, Manca D, Natarajan N, Terry A, Wong S, Martin RE, Mangin D. (2015). Horses and buggies have some advantages over cars, but no one is turning back. Canadian Family Physician. 61(5): 416-419.
  • da Silva A L, Mangin D, Pizzanelli M, Jamoulle M, Wagner HL, Silva D, de Lima R, Batista S, Soares J, Rochadel A, Cardoso R, Filho E, Duro L, Teixeira T, Sens G, Júnio W. (2014). Manifesto de Curitiba: pela Prevenção Quaternária e por uma Medicina sem conflitos de interesse. Revista Brasileira de Medicina de Família e Comunidade. 9(33): 371-374.
  • Mangin D. (2014). Ethical issues related to health checks. BMJ (Clinical research ed.). 349: g4787.
  • Brookwell L , Hogan C , Healy D , Mangin D. (2014). Ninety-three cases of alcohol dependence following SSRI treatment. The International Journal of Risk & Safety in Medicine. 26(2): 99-107. doi: 10.3233/JRS-140616
  • Healy D, Howe G , Mangin D , Le Noury J. (2014). Sudden Cardiac Death & the Reverse Dodo Verdict. The International Journal of Risk & Safety in Medicine. 26(2): 71-9. doi: 10.3233/JRS-140615
  • Hogan C, Le Noury J, Healy D, Mangin D. (2014). One hundred and twenty cases of enduring sexual dysfunction following treatment. The International Journal of Risk & Safety in Medicine. 26(2): 109-16. doi: 10.3233/JRS-140617

 

*= Mangin, D

Selected Grants:

 

  • Principal Investigator: Canadian Institutes for Health Research (CIHR) – 2016 1st Live Pilot (2016-2020). Team Approach to Polypharmacy Evaluation and Reduction (TAPER) ($974,737)
  • Co-investigator: Canadian Frailty Network (CFN), Catalyst Grant (2016-2017) The eDosette Study: Optimizing medication use and safety in community dwelling seniors ($100,000)
  • Co-investigator: Canadian Institutes of Health Research (CIHR) (2015 – 2020) The Drug Safety and Effectiveness Cross-Disciplinary Training (DSECT) Program ($1,373,522)
  • Co-investigator: Health Research Foundation Academic Interdisciplinary Health Research Team Grant (2015-2017) Integrating Rehabilitation Principles into Interdisciplinary Self-Management – A Health Strategy for Chronic Disease and Aging ($200,000)
  • Principal Investigator: Labarge Optimal Aging Opportunities Fund (2016-2017) TAPER-F: Team Approach to Polypharmacy Evaluation and Reduction ($75,000)
  • Principal Investigator: Canadian Institutes of Health Research (CIHR) (2015-2016) Postpartum domperidone use to stimulate breast milk supply: do maternal and infant health benefits outweigh potential harm? A systematic review ($100,000)
  • Co-investigator: Technology Evaluation in the Elderly Network (TVN) (2015-2016) The eDosette Study: Optimizing medication use and safety in community dwelling seniors ($20,000)
  • Principal Investigator: McMaster University, Department of Family Medicine Pilot Research Funding Grant (2014-2015) Deprescribing to Optimize Medicine Use and Safety in Seniors ($5,000)
  • Co-investigator: Ontario Medical Association/Ministry of Long Term Care (2014- 2015) Medical Rapid Education and Assessment for Complete Health (MedREACH) Project: Addressing unmet health needs of medically complex patients through collaboration between primary and specialist care ($750,000)
  • Co-investigator: Health Research Council of New Zealand (2014) A randomized controlled trial of nortriptyline in knee osteoarthritis ($1,190,921)
  • Co-investigator: Health Research Council of New Zealand (2014) Multimorbidity: the most common chronic condition of all ($1,199,968)
  • Principal Investigator: Health Research Council of New Zealand (2008-2014) Stable primary care depression: maintenance vs gradual withdrawal of fluoxetine ($1,700,000)
  • Principal Investigator: University of Otago Research Grant 2009  and Canterbury Medical Research Foundation Research Grants 2009 Cognitive and Behavioural Outcomes in Long Term Selective Serotonin Reuptake Inhibitor Use  ($100,000)
  • Co-investigator: Ontario Medical Association / Ministry of Long Term Care Demonstration Project Funding The MedREACH Project – Addressing unmet health needs of medically complex patients through collaboration between primary and specialist care ($750,000)